Arb vs acei
Pro Research Analysisby 
Searched over 200M research papers
Comparative Analysis of ARBs and ACEIs in COVID-19 Outcomes
Introduction to ARBs and ACEIs in COVID-19 Context
Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are commonly prescribed for managing hypertension and other cardiovascular conditions. With the onset of the COVID-19 pandemic, concerns emerged regarding the safety and efficacy of these medications due to their potential impact on ACE2 receptors, which SARS-CoV-2 uses to enter human cells Sriram2020Yang2020. This article synthesizes current research to compare the effects of ARBs and ACEIs on COVID-19 susceptibility, severity, and mortality.
COVID-19 Susceptibility and ACEI/ARB Use
Several studies have investigated whether ACEI/ARB use increases the risk of contracting COVID-19. A systematic review and meta-analysis found no significant association between ACEI/ARB use and the risk of SARS-CoV-2 infection in the general population (adjusted OR 1.00, 95% CI 0.94-1.05) . This finding is consistent across various populations and drug exposures, suggesting that ACEI/ARB use does not increase susceptibility to COVID-19 Zhang2020Sriram2020.
Impact on COVID-19 Severity
The severity of COVID-19 among patients using ACEIs or ARBs has been a critical area of research. Multiple studies indicate that ACEI/ARB use does not significantly affect the severity of COVID-19. For instance, a meta-analysis of East-Asian patients showed no statistically significant difference in disease severity between those receiving ACEI/ARB and those who were not (OR = 0.99, 95% CI 0.83-1.17) . Similarly, another study found no increased risk of severe outcomes among COVID-19 patients taking these medications (aOR 0.95, 95% CI 0.73-1.24) .
Mortality Rates and Clinical Outcomes
Research consistently shows that ACEI/ARB use is not associated with higher mortality rates in COVID-19 patients. In fact, some studies suggest a protective effect. A meta-analysis reported that ACEI/ARB use was associated with a lower mortality rate (OR = 0.61, 95% CI 0.52-0.70) and shorter hospital stays among East-Asian patients . Another study found that continued in-hospital use of ACEIs/ARBs was linked to significantly lower ICU admission and mortality rates compared to discontinuation of these medications .
Comparative Efficacy of ARBs vs. ACEIs
When comparing ARBs and ACEIs directly, some studies suggest that ARBs may offer a slight advantage in reducing mortality. A systematic review found that ARB use was associated with reduced mortality (OR 0.51, 95% CI 0.29-0.90), whereas ACEI use did not show a statistically significant reduction in mortality (OR 0.68, 95% CI 0.39-1.17) . This finding aligns with another study that highlighted the blood pressure-independent benefits of ACEIs in reducing the risk of major coronary disease events, a benefit not observed with ARBs .
Conclusion
Current evidence supports the continued use of ACEIs and ARBs in patients with COVID-19, as these medications do not increase the risk of infection or severe outcomes. In fact, they may offer protective benefits, particularly in reducing mortality and ICU admissions. While both drug classes are effective, ARBs may have a slight edge in reducing mortality rates. Therefore, patients on these medications should continue their use under medical guidance, especially during the COVID-19 pandemic.
Sources and full results
Most relevant research papers on this topic
Systematic review and meta-analysis of the clinical outcomes of ACEI/ARB in East-Asian patients with COVID-19
ACEI/ARB treatment in East-Asian COVID-19 patients is associated with reduced mortality and shorter hospital stays, without adverse clinical outcomes.
Risks of ACE Inhibitor and ARB Usage in COVID‐19: Evaluating the Evidence
ACE inhibitors and ARBs do not increase ACE2 expression and do not increase the risk of complications from COVID-19, so patients should continue their use for approved indications.
The Effect of Prior ACEI/ARB Treatment on COVID-19 Susceptibility and Outcome: A Systematic Review and Meta-Analysis
Prior ACEI/ARB treatment does not increase COVID-19 susceptibility or disease severity, supporting current medical guidelines that ACEI/ARB should not be discontinued.
DOI